Madelyn A Gillentine1,2, Janson J White1, Christopher M Grochowski1, James R Lupski1,3,4, Christian P Schaaf1,2, Chadi A Calarge5. 1. 1 Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, Texas. 2. 2 Jan and Dan Neurological Research Institute, Texas Children's Hospital , Houston, Texas. 3. 3 Human Genome Sequencing Center, Baylor College of Medicine , Houston, Texas. 4. 4 Texas Children's Hospital , Houston, Texas. 5. 5 Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine , Houston, Texas.
Abstract
OBJECTIVE: Aggression is among the most common indications for referral to child and adolescent mental health services and is often challenging to treat. Understanding the biological underpinnings of aggression could help optimize treatment efficacy. Neuronal nicotinic acetylcholine receptors (nAChRs), specifically the α7 nAChR, encoded by the gene CHRNA7, have been implicated in aggressive behaviors in animal models as well as humans. Copy number variants (CNVs) of CHRNA7 are found in individuals with neuropsychiatric disorders, often with comorbid aggression. In this study, we aimed to determine the prevalence of CHRNA7 CNVs among individuals treated with risperidone, predominantly for irritability and aggression. METHODS: Risperidone-treated children and adolescents were assessed for CHRNA7 copy number state using droplet digital PCR and genomic quantitative PCR. Demographic, anthropometric, and clinical data, including the Child Behavior Checklist (CBCL), were collected and compared across individuals with and without the CHRNA7 deletion. RESULTS: Of 218 individuals (90% males, mean age: 12.3 ± 2.3 years), 7 (3.2%) were found to carry a CHRNA7 deletion and one proband carried a CHRNA7 duplication (0.46%). T-scores for rule breaking, aggression, and externalizing behavior factors of the CBCL were higher in the deletion group, despite taking 58% higher dose of risperidone. CONCLUSIONS: CHRNA7 loss may contribute to a phenotype of severe aggression. Given the high prevalence of the deletion among risperidone-treated youth, future studies should examine the therapeutic potential of α7 nAChR-targeting drugs to target aggression associated with CHRNA7 deletions.
OBJECTIVE:Aggression is among the most common indications for referral to child and adolescent mental health services and is often challenging to treat. Understanding the biological underpinnings of aggression could help optimize treatment efficacy. Neuronal nicotinic acetylcholine receptors (nAChRs), specifically the α7 nAChR, encoded by the gene CHRNA7, have been implicated in aggressive behaviors in animal models as well as humans. Copy number variants (CNVs) of CHRNA7 are found in individuals with neuropsychiatric disorders, often with comorbid aggression. In this study, we aimed to determine the prevalence of CHRNA7 CNVs among individuals treated with risperidone, predominantly for irritability and aggression. METHODS:Risperidone-treated children and adolescents were assessed for CHRNA7 copy number state using droplet digital PCR and genomic quantitative PCR. Demographic, anthropometric, and clinical data, including the Child Behavior Checklist (CBCL), were collected and compared across individuals with and without the CHRNA7 deletion. RESULTS: Of 218 individuals (90% males, mean age: 12.3 ± 2.3 years), 7 (3.2%) were found to carry a CHRNA7 deletion and one proband carried a CHRNA7 duplication (0.46%). T-scores for rule breaking, aggression, and externalizing behavior factors of the CBCL were higher in the deletion group, despite taking 58% higher dose of risperidone. CONCLUSIONS:CHRNA7 loss may contribute to a phenotype of severe aggression. Given the high prevalence of the deletion among risperidone-treated youth, future studies should examine the therapeutic potential of α7 nAChR-targeting drugs to target aggression associated with CHRNA7 deletions.
Authors: M A Gillentine; L N Berry; R P Goin-Kochel; M A Ali; J Ge; D Guffey; J A Rosenfeld; V Hannig; P Bader; M Proud; M Shinawi; B H Graham; A Lin; S R Lalani; J Reynolds; M Chen; T Grebe; C G Minard; P Stankiewicz; A L Beaudet; C P Schaaf Journal: J Autism Dev Disord Date: 2017-03
Authors: Mark N Ziats; Robin P Goin-Kochel; Leandra N Berry; May Ali; Jun Ge; Danielle Guffey; Jill A Rosenfeld; Patricia Bader; Michael J Gambello; Varina Wolf; Lynette S Penney; Ryan Miller; Robert Roger Lebel; Jeffrey Kane; Kristine Bachman; Robin Troxell; Gary Clark; Charles G Minard; Pawel Stankiewicz; Arthur Beaudet; Christian P Schaaf Journal: Genet Med Date: 2016-03-10 Impact factor: 8.822
Authors: Katrin Männik; Reedik Mägi; Aurélien Macé; Ben Cole; Anna L Guyatt; Hashem A Shihab; Anne M Maillard; Helene Alavere; Anneli Kolk; Anu Reigo; Evelin Mihailov; Liis Leitsalu; Anne-Maud Ferreira; Margit Nõukas; Alexander Teumer; Erika Salvi; Daniele Cusi; Matt McGue; William G Iacono; Tom R Gaunt; Jacques S Beckmann; Sébastien Jacquemont; Zoltán Kutalik; Nathan Pankratz; Nicholas Timpson; Andres Metspalu; Alexandre Reymond Journal: JAMA Date: 2015-05-26 Impact factor: 56.272
Authors: Nigel M Williams; Barbara Franke; Eric Mick; Richard J L Anney; Christine M Freitag; Michael Gill; Anita Thapar; Michael C O'Donovan; Michael J Owen; Peter Holmans; Lindsey Kent; Frank Middleton; Yanli Zhang-James; Lu Liu; Jobst Meyer; Thuy Trang Nguyen; Jasmin Romanos; Marcel Romanos; Christiane Seitz; Tobias J Renner; Susanne Walitza; Andreas Warnke; Haukur Palmason; Jan Buitelaar; Nanda Rommelse; Alejandro Arias Vasquez; Ziarih Hawi; Kate Langley; Joseph Sergeant; Hans-Christoph Steinhausen; Herbert Roeyers; Joseph Biederman; Irina Zaharieva; Hakon Hakonarson; Josephine Elia; Anath C Lionel; Jennifer Crosbie; Christian R Marshall; Russell Schachar; Stephen W Scherer; Alexandre Todorov; Susan L Smalley; Sandra Loo; Stanley Nelson; Corina Shtir; Philip Asherson; Andreas Reif; Klaus-Peter Lesch; Stephen V Faraone Journal: Am J Psychiatry Date: 2012-02 Impact factor: 18.112
Authors: S M Bahr; B C Tyler; N Wooldridge; B D Butcher; T L Burns; L M Teesch; C L Oltman; M A Azcarate-Peril; J R Kirby; C A Calarge Journal: Transl Psychiatry Date: 2015-10-06 Impact factor: 6.222
Authors: Alan S Lewis; Gerrit Ian van Schalkwyk; Mayra Ortiz Lopez; Fred R Volkmar; Marina R Picciotto; Denis G Sukhodolsky Journal: J Autism Dev Disord Date: 2018-08
Authors: Alan S Lewis; Steven T Pittenger; Yann S Mineur; Dawson Stout; Philip H Smith; Marina R Picciotto Journal: Neuropsychopharmacology Date: 2017-11-07 Impact factor: 7.853